Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia
Molecular Therapy · 2023
DOI: 10.1016/j.ymthe.2023.01.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2023. Verfasst von Santhosh Kumar Pasupuleti und 11 weiteren Autor:innen. Beteiligte Einrichtung: Herman B. Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, 1044 W. Walnut Street, R4-168, Indian…. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Juvenile. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative neoplasm of childhood. The molecular hallmark of JMML is hyperactivation of the Ras/MAPK pathway with the most common cause being mutations in the gene PTPN11, encoding the protein tyrosine phosphatase SHP2. Current strategies for treating JMML include using the hypomethylating agent, 5-azacitidine (5-Aza) or MEK inhibitors trametinib and PD0325901 (PD-901), but none of these are curative as monotherapy. Utilizing an Shp2E76K/+ murine model of JMML, we show that the combination of 5-Aza and PD-901 modulates several hematologic abnormalities often seen in JMML patients, in part by reducing the burden of leukemic hematopoietic stem and progenitor cells (HSC/Ps). The reduced JMML features in drug-treated mice were associated with a decrease in p-MEK and p-ERK levels in Shp2E76K/+ mice treated with the combination of 5-Aza and PD-901. RNA-sequencing analysis revealed a reduction in several RAS and MAPK signaling-related genes. Additionally, a decrease in the expression of genes associated with inflammation and myeloid leukemia was also observed in Shp2E76K/+ mice treated with the combination of the two drugs. Finally, we report two patients with JMML and PTPN11 mutations treated with 5-Aza, trametinib, and chemotherapy who experienced a clinical response because of the combination treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Herman B. Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, 1044 W. Walnut Street, R4-168, Indianapolis, IN 46202, USA.
- Department of Pediatrics, Children's Wisconsin, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Stanford University School of Medicine, Lucile Packard Children's Hospital, Palo Alto, CA, USA.
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
- Seattle Children's Hospital, Seattle, WA, USA.
- Department of Pediatrics, Benioff Children's Hospital, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
- Department of Pediatrics, Children's Wisconsin, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: mmburke@mcw.edu.
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NIGMS NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
- National Cancer Institute
- V Foundation for Cancer Research
- Riley Children's Foundation
Zitieren
APA
Pasupuleti, S. K., Chao, K., Ramdas, B., Kanumuri, R., Palam, L. R., Liu, S., Wan, J., Annesley, C., Loh, M. L., Stieglitz, E., Burke, M. J., & Kapur, R. (2023). Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2023.01.030
Vancouver
Pasupuleti SK, Chao K, Ramdas B, Kanumuri R, Palam LR, Liu S, et al. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia. Molecular Therapy. 2023. doi:10.1016/j.ymthe.2023.01.030
BibTeX
@article{Pasupuleti2023,
author = {Pasupuleti, Santhosh Kumar and Chao, Karen and Ramdas, Baskar and Kanumuri, Rahul and Palam, Lakshmi Reddy and Liu, Sheng and Wan, Jun and Annesley, Colleen and Loh, Mignon L and Stieglitz, Elliot and Burke, Michael J and Kapur, Reuben},
title = {Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia},
journal = {Molecular Therapy},
year = {2023},
doi = {10.1016/j.ymthe.2023.01.030}
}
EUVIMED